Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc.

Overview
Date Founded

1995

Headquarters

420 SAW MILL RIVER ROAD, ARDSLEY, NY, 10502

Type of Company

Public

Employees (Worldwide)

474

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Contact Data
Trying to get in touch with decision makers at Acorda Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder, President & Chief Executive Officer

President, International, General Counsel & Corporate Secretary

Executive Vice President, Commercial Development

Chief Scientific Officer Emeritus

Principal Accounting Officer

Chief Medical Officer, Head-R&D

Chief Business Officer

Executive Vice President, Corporate Communications

Executive Vice President, Human Resources

Senior Vice President, Quality

Board of Directors

President at Alnylam Pharmaceuticals, Inc.

Professional at Acorda Therapeutics, Inc.

Managing Partner at Cross Atlantic Partners, Inc.

Founder at Bay Way Consultants LLC

Professional at Athersys, Inc.

Founding Partner at Synergy Partners R&D Solutions

Paths to Acorda Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Acorda Therapeutics, Inc.
Owners & Shareholders
Details Hidden

SCM employs a fundamentals-based, value-driven investment approach across four strategies: a long-short equity strategy managed with the discipline of market neutrality, a long-short equity strategy managed with net long exposure, a long-only equity strategy and a long-short health care focused strategy. The firm seeks to identify investments primarily in publicly-traded equities (on both US and non-US exchanges), including IPOs, but may also include options, derivatives and bonds that they believe will increase in value (or at least maintain their value) even in a falling market, and conversely to identify and sell short stocks that they believe will drop in value (or at least under-perform) regardless of the industry and the market's overall direction. The long portfolio focuses on dynamic companies protected by low valuations relative to free cash flow, strong cash positions or valuable intellectual property and sensible business models. The short portfolio selects companies that SCM determines are not only overvalued, but also fundamentally flawed because of the poor prospects of their products or services. The research process combines examining publicly available financial data and conducting in-depth proprietary field research.

Details Hidden

PFM generally uses bottom-up analysis to identify trends, investment themes and core investment opportunities across asset classes and geographies in a wide range of investment instruments. The firm may invest in various industries or sectors, including, but not limited to, communications and media, consumer, energy, financials, healthcare, industrials, materials, technology and utilities. Their main investment strategies include diversified global and healthcare. PFM seeks to identify out- and under-performing companies that have the widest expectation gaps relative to consensus. In some cases, they may apply a catalyst-driven investment approach to express their fundamental view with respect to a company. PFM may also engage in top-down macro-economic analysis to identify opportunities, whether on a directional or relative value basis, across a wide range of global markets and investment instruments. They may consider economic, political and financial market conditions in seeking to identify attractive investment opportunities. The firm invests in and trades a wide range of investment instruments, including securities, options, ETFs, futures, currencies, derivatives, debt instruments and other assets that are financial instruments. They take both long and short positions in such investment instruments.

Details Hidden

Nexthera Capital LP is an American private company located in New York, NY, with operations in KY, that provides investment advice. It was founded in 2015 by Ori Hershkovitz and Daniel Malek. Daniel Malek has been the CEO since that date.

Recent Transactions
Details Hidden

Acorda Therapeutics, Inc. purchases Biotie Therapies Corp.

Details Hidden

Acorda Therapeutics, Inc. purchases Civitas Therapeutics, Inc. from Fountain Healthcare Partners Ltd., Canaan Management, Inc., Sofinnova Ventures, Inc., Bay City Capital LLC, OrbiMed Advisors Private Equity, Longitude Capital Management Co. LLC

Details Hidden

Acorda Therapeutics, Inc. purchases Neuronex, Inc.

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onAcorda Therapeutics, Inc. issued Common Stock

Underwriter

Advised onAcorda Therapeutics, Inc. issued Common Stock

Underwriter

Advised onAcorda Therapeutics, Inc. issued Common Stock

Associate

Advised onAcorda Therapeutics, Inc. purchases Civitas Therapeutics, Inc. from Fountain Healthcare Partners Ltd., Canaan Management, Inc., Sofinnova Ventures, Inc., Bay City Capital LLC, OrbiMed Advisors Private Equity, Longitude Capital Management Co. LLC

Legal Advisor

Advised onAcorda Therapeutics, Inc. purchases Civitas Therapeutics, Inc. from Fountain Healthcare Partners Ltd., Canaan Management, Inc., Sofinnova Ventures, Inc., Bay City Capital LLC, OrbiMed Advisors Private Equity, Longitude Capital Management Co. LLC

Legal Advisor

Advised onAcorda Therapeutics, Inc. purchases Civitas Therapeutics, Inc. from Fountain Healthcare Partners Ltd., Canaan Management, Inc., Sofinnova Ventures, Inc., Bay City Capital LLC, OrbiMed Advisors Private Equity, Longitude Capital Management Co. LLC

Advisors & Consultants
Consultant

Chief Financial Officer & Principal Financial & Accounting Officer at Aerpio Pharmaceuticals, Inc.

Consultant

Professional at Marinus Pharmaceuticals, Inc.

Legal Advisor

Partner at Jones Day

Clients

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 46,000 employees worldwide. Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence

AmerisourceBergen Corp. engages provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and includes ABCS, World Courier, and MWI. The company is headquartered in Chesterbrook, PA.

Key Stats and Financials As of 2018
Market Capitalization
$632M
Total Enterprise Value
$666M
Earnings Per Share
$0.71
Revenue
$471M
Net Profit
$33.7M
EBITDA
$98.5M
EBITDAMargin
20.89%
Total Debt
$374M
Total Equity
$612M
Enterprise Value Sales
1.41x
Enterprise Value EBITDAOperating
6.76x
TEVNet Income
19.77x
Debt TEV
0.56x
Three Year Compounded Annual Growth Rate Of Revenue
-1.46%
Five Year Compounded Annual Growth Rate Of Revenue
6.98%
Non-Profit Donations & Grants Received
Political Donations
$1,000
2008
$500
2006
Investors
Details Hidden

Cross Atlantic focuses only on US-based healthcare opportunities, especially in drug discovery, devices and services. They place emphasis on oncology, neurological diseases and infectious diseases. They look for companies seeking to develop more effective, less expensive products or services which reduce the need for surgery or hospitalization and provide higher quality care at a lower cost.Cross Atlantic invests in companies beyond the start-up stage. They seek companies whose innovative products show clear competitive advantages. Such products should be based on proprietary technology or specialized service expertise and should meet significant market needs. In-depth review of patent portfolios is a standard part of their due diligence.The firm expects at least a 3X return of capital with an average holding period of 4 years. Exit strategies may include the sale of securities through IPOs, secondary public and private offerings, sales in connection with strategic alliance/corporate partnering transactions or merger and acquisition transactions.

Details Hidden

Easton invests in all segments of the healthcare industry, including biopharmaceuticals, drug delivery, medical devices and healthcare services. They look for high-caliber teams with industry experience and a demonstrated ability to deliver results. Easton assists in identifying and recruiting additional management talent.Easton prefers to invest alongside other strong financial players to provide maximum value to the company and to ensure the availability of adequate growth capital. The firm is stage-agnostic and considers opportunities from early-stage venture capital to later-stage growth capital with investment size ranging from $0.05 - $10 million. They are generally not a seed-stage investor.

Details Hidden

Paul Capital Partners' investment platforms include the Paul Capital Fund of Funds, secondary investments and commercial-stage healthcare investments.The Paul Capital Fund of Funds investment team focuses on investments in venture capital and small-cap buyouts. The firm invests in funds that support innovative products and business models. They take takes a lead investment role and actively seek advisory board seats. Their strategy is both growth and value oriented.The Paul Capital Fund of Funds venture capital investment strategy focuses on providing access to top-tier venture capital managers. The firm looks for emerging managers that have the potential to become industry leaders. They employ a multi-industry investment strategy that focuses on information technology, healthcare and clean technology. Most investments are made in early-stage companies, but some investments are made in late-stage and growth equity to provide reduced volatility and more rapid exits. The strategy is biased towards small funds and is balanced by a short list of larger funds or platforms. Paul Capital invests primarily in funds in the Silicon Valley and Boston, with growing exposure to select international investments. They make secondary investments in top tier managers obtained through the secondary market to mitigate the effect of the typical J-Curve associated with private equity fund investing.The Paul Capital Fund of Funds small-cap buyout investment strategy focuses on investments in a small-cap buyout funds in North America. They invest in small-cap buyout funds that are being raised by managers who are focused on buying companies with enterprise values of $300 million or less. To select the best performing managers, Paul Capital's process begins with a large universe of buyout relationships and ends with a focused and diversified small-cap buyout portfolio. The portfolio is complemented by co-investments and by investments in target funds obtained through the secondary market.The Paul Capital Fund of Funds co-investment strategy focuses on co-investments alongside general partners that are well-known to the firm and who require capital to close pending small-cap buyout and growth equity transactions. Investments are made directly in the securities of the portfolio company. The Fund of Funds team invests directly in portfolio companies across a full range of economic and credit cycles.For investors requiring exposure to both the firm's venture capital and small-cap buyout funds, Paul Capital provides customized solutions that allow participation in both activities over a multi-year period with a desired percentage allocation to each. Large investors seeking increased exposure to emerging managers, growth equity funds or buyout funds larger than their small-cap target (but generally less than $2 billion in size) can be accommodated through a separate account relationship.Paul Capital provides secondary transaction solutions for various sellers including pension plans, financial institutions, endowments, family offices, corporations and general partners.They help sellers reallocate their portfolio across asset types and classes, achieve early liquidity from private equity investments and obtain follow-on capital for existing portfolios and other objectives.Paul Capital Healthcare employs a variety of financing options ranging from non-dilutive financings that include royalty and revenue interest financings, to more traditional instruments such as equity and structured debt. Their clients include public and private companies, academic institutions and inventors. Paul Capital Healthcare helps companies monetize their royalty streams by selling all or a portion of these future royalties in exchange for an upfront payment and, depending on the structure, potential future payments. Paul Capital Healthcare invests in healthcare products that are approved and are generating revenue or are near commercialization. Healthcare companies should have an identifiable and established market, have patent and/or regulatory protection and be marketed by a strong organization.Paul Capital Healthcare employs the use of synthetic royalties or revenue interest financings. The firm provides a company with an upfront payment and future payments in exchange for a percentage of future product revenues. These deals are structured in a way that is similar to licensing agreements. They employ tiered revenues, reverse tiers, minimum payments, caps, step-downs and buy-out options. The deals are different from a standard licensing agreement in that Paul Capital Healthcare is not responsible for commercializing the product and is not involved in the company's daily operations. The firm makes an upfront payment to the company and, in some cases, additional payments based on certain milestones, such as regulatory approvals, patent extensions and sales targets. Paul Capital Healthcare then receives a portion of the future revenues generated by the product(s).Paul Capital Healthcare provides structured debt financing for small to mid-sized healthcare companies looking to expand operations. They can structure mezzanine-like debt in combination with revenue interests or royalty financings and the purchase of equities.Paul Capital Healthcare also structures traditional equity investments, usually in combination with revenue interest and royalty financings. The Fund participates in early-stage financing rounds in syndication with venture funds and in PIPE-style offerings. Paul Capital Healthcare focuses on near market or commercial-stage investments.

Suppliers
Patheon, Inc. Pharmaceuticals | Mississauga, ON

Patheon, Inc. provides drug development and manufacturing services to global pharmaceutical, biotechnology and specialty pharmaceutical companies. It operates through two segments: Commercial Manufacturing Outsourcing and Pharmaceutical Development Services. The Commercial Manufacturing Outsourcing segment manufactures prescription products in sterile dosage forms as well as solid and liquid conventional dosage forms. The Pharmaceutical Development Services segment provides a broad range of development services, including solid and sterile dosage forms. The company operates through four market segments: Biologics, Emerging Pharma, Generics and Large Pharma. Patheon was founded in 1974 and is headquartered in Mississauga, Canada.

Alkermes Plc Pharmaceuticals | Dublin, DU

Alkermes is a leader in innovative medicines that address the unmet needs and challenges of people living with debilitating diseases. As a fully integrated global biopharmaceutical company, Alkermes applies our scientific expertise, proprietary technologies, and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease.

Regis Technologies, Inc. Chemicals | Morton Grove, IL

Regis Technologies, Inc. is a private company headquartered in Morton Grove, IL. The firm manufactures pharmaceutical ingredients for drug preparation.

Competitors
Sanofi Pharmaceuticals - Paris, IF

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Middlesex

GlaxoSmithKline Plc is a global healthcare company which engages in researching, developing and manufacturing of pharmaceutical medicines, vaccines and consumer healthcare products. It operates through the following four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals segment researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare segment markets a range of consumer health products based on scientific innovation. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Allergan Plc Pharmaceuticals - Dublin, DU

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Acorda Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Acorda Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Acorda Therapeutics, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/acorda-therapeutics-inc-87035
  • https://relationshipscience.com/organization/acorda-therapeutics-inc-87035